MEDICINAL CHEMISTRY FACILITY

药物化学设施

基本信息

批准号：
8926334
负责人：
GREGG PIOSKE
金额：
$ 155.95万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-30 至 2018-09-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8926334
关键词：
Agonist Ants Area Binding Cataloging Catalogs Chemical Agents Chemicals Chemistry Contraceptive Agents Contraceptive methods Contractor Contracts Data Development Female Contraceptive Agents Fertility Fertility Agents Goals Government Human Resources Label Laboratories Laws Male Contraceptive Agents Mass Spectrum Analysis Nuclear Magnetic Resonance Optical Rotation Peptide Synthesis Pharmaceutical Chemistry Pharmaceutical Preparations Pregnancy Process Proteins Publishing Qualifying Radio Radioactivity Regulation Research Research Personnel Research Support Resources Role Route Services Structure Synthesis Chemistry Testing United States Woman Work Writing contraceptive target cost design drug discovery female reproductive system instrumentation interest male men milligram novel pre-clinical programs reproductive small molecule ultraviolet

项目摘要

Nearly half of all pregnancies in the United States are unintended. Thus, there is a critical need for fertility regulation that fits the needs of women and men throughout their reproductive lives. The Contraceptive Discovery and Development Branch (CDDB) support research in the synthesis and testing of a broad spectrum of male and female contraceptive agents. Successful development of new contraceptive methods for men and women has been a goal for many decades. From the inception of this program in1976, the CDDB has had a continuing need for the discovery chemistry and the subsequent development of the anti-fertility agents. The Medicinal Chemistry Facility (MCF) fulfills a unique role in bridging the discovery of contraceptive targets to the development and approval of the contraceptive drug. To this end, the research at the MCF will encompass discovery and optimization of small molecule antagonist or agonists of protein targets as anti-fertility agents. In addition, the MCF has an important role in enriching and providing pre-clinical antifertility drug pipeline. The Scope of this contract is for the Medicinal Chemistry Facility to carry out integrated drug discovery and optimization of anti-fertility agents on protein targets specific to male or female reproductive system.

在美国，几乎一半的怀孕是意想不到的。因此，对在生殖生活中，适合男女需求的生育监管。这避孕发现与发展分支（CDDB）支持合成中的研究测试一系列男性和女性避孕药。成功发展数十年来，男女的新避孕方法一直是一个目标。来自 CDDB在1976年开始了该计划的成立，对发现化学一直不断需求以及随后的抗肥药剂的发展。药物化学设施（MCF）在将避孕目标桥接到开发方面发挥了独特的作用并批准避孕药。为此，MCF的研究将包括发现和优化蛋白质靶标的小分子拮抗剂或激动剂作为抗精神代理商。此外，MCF在富集和提供临床前的抗细性方面具有重要作用药物管道。该合同的范围是药物化学设施进行综合药物针对男性或女性的蛋白质靶标发现和优化抗肥药剂生殖系统。